Hot-Topic Roundup

June 2012
Pharmaceutical Technology;Jun2012, Vol. 36 Issue 6, p28
Trade Publication
The article offers information on various issues related to regulations for medical products in the U.S. It mentions that the budget of the U.S. Food and Drug Administration (FDA) will face a challenge in the U.S. Senate. It states the plan of FDA to make policies on the development of drugs, medical devices, and cosmetics with nanotechnology. It says that Comparative Effectiveness Research (CER) could affect the drug development.


Related Articles

  • Introduction: designing nanobiotechnology oversight. Fatehi, Leili; Wolf, Susan; Ramachandran, Gurumurthy; Kuzma, Jennifer // Journal of Nanoparticle Research;Apr2011, Vol. 13 Issue 4, p1341 

    No abstract available.

  • Oxymorphone HCl Extended-Release Tablets (Opana ER) CII. Elliott, William T.; Chan, James // Internal Medicine Alert;1/15/2012, Vol. 34 Issue 1, p5 

    The article presents information on the indications, dosage, advantages and clinical implications of a new formulation of oxymorphone extended-release tablets marketed by Endo and approved by the U.S. Food and Drug Administration (FDA).

  • Recent confusion and ongoing actions related to the FDA's Inactive Ingredient Database (IID) - What should be included in the ANDA? Schoneker, David R. // Journal of Excipients & Food Chemicals;Sep2015, Vol. 6 Issue 3, p94 

    The author comments on the confusion and actions related to the Inactive Ingredient Database (IID) of the U.S. Food and Drug Administration (FDA), and the maximum potency and maximum daily intake level to be included in the Abbreviated New Drug Application (ANDA).

  • FDA: more funds needed for drug review.  // Medical Marketing & Media;Dec2001, Vol. 36 Issue 12, p6 

    Reports on the failure of the U.S. Food and Drug Administration to meet the goals set by the Prescription Drug User Fee Act for new drug review and clearance. Need for additional funds; Citation of increased approval time; Decline of user fees.

  • When Data's Scarce The Grass Is Greener. Glenn, Christopher // Review of Ophthalmology;Sep2012, Vol. 19 Issue 9, p15 

    An introduction is presented in which the editor discusses various reports within the issue on topics such as the systematic review of studies comparing the European medical device approval process and the U.S. Food and Drug Administration (FDA) approval procedure and the U.S. approval process...

  • Left to their own devices. Volokh, Alexander // Reason;Jan95, Vol. 26 Issue 8, p16 

    Reports that thousands of Americans die every year because the Food and Drug Administration (FDA) denies them access to life-saving medical devices. Submission of `pre-market notification'; More time spent on review of applications; FDA's call for increased regulatory power.

  • FDA seeks public input on medical mobile app oversight project.  // Endocrine Today;Aug2011, Vol. 9 Issue 8, p7 

    The article reports on the plan of the U.S. Food and Drug Administration to gather input from the public regarding its proposed oversight approach for mobile medical applications designed for smartphones and other mobile computing devices.

  • FDA to seek public comment on recommendations to the 510(k) program.  // Infectious Disease News;Sep2011, Vol. 24 Issue 9, p35 

    The article reports on the public comment being sought by the U.S. Food and Drug Administration (FDA) for recommendations to the 510(k) medical device review program.

  • Are you ready? FDA final rules on devices are on the way. Berek, Britton // Health Facilities Management;Sep96, Vol. 9 Issue 9, p56 

    Discusses the regulations issued by the United States Food and Drug Administration (FDA) on how to report incidents involving medical devices. Regulations under the Safe Medical Devices Act; Persons exempted from the act; Reports to be submitted by device-user facilities to the FDA; Submission...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics